颈清扫对颈段食管鳞癌伴颈部淋巴结转移患者的疗效回顾性研究
该研究回顾性分析180例接受手术的颈段食管鳞癌患者,比较颈部淋巴结转移区域及术前干预对生存的影响。结果显示无淋巴结转移者5年OS率显著更高,中央区与联合侧颈区转移者5年OS率无显著差异,术前化疗联合免疫治疗可显著降低死亡风险并提高3年OS率。
要点
- 无颈部淋巴结转移者5年OS率显著高于有转移者(54.86% vs 35.69%)。
- 中央区与联合侧颈区转移者5年OS率无显著差异。
- 术前化疗联合免疫治疗可显著降低死亡风险并提高3年OS率。
核心结论
- 侧颈区淋巴结转移患者接受颈清扫后手术疗效与仅中央区转移者相近。
- 术前化疗联合免疫治疗可有效提高颈段食管鳞癌患者总体生存率。
研究设计与样本
- 回顾性分析2001年2月至2023年10月中国医学科学院肿瘤医院180例接受手术的颈段食管鳞癌患者。
- 男性141例,女性39例,年龄24~76岁,中位年龄59岁。
- 按颈部淋巴结转移区域分为无转移组、仅中央区转移组、中央区和侧颈区联合转移组。
主要发现
- 全组中位OS为46个月,3年OS率58.04%,5年OS率42.02%。
- 无颈部淋巴结转移组(57例)5年OS率54.86%,有转移者35.69%,差异有统计学意义(χ2=7.29,P=0.007)。
- 中央区转移组(54例)与联合转移组(69例)5年OS率分别为35.98%和35.36%,差异无统计学意义(χ2=0.17,P=0.676)。
- 术前化疗和化疗联合免疫治疗降低死亡风险(HR=0.61和0.12,P值均<0.05)。
- 3年OS率在化疗联合免疫治疗组(90.91%)、术前化疗组(65.89%)和术前未化疗组(49.68%)间差异有统计学意义(χ2=11.22,P=0.004)。
临床怎么用
- 对颈段食管鳞癌伴颈部淋巴结转移患者,颈清扫后侧颈区转移与中央区转移疗效相近。
- 术前化疗联合免疫治疗可作为提高生存率的治疗策略。
局限性
- 本文为回顾性单中心研究,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the surgical outcomes in cervical esophageal squamous cell carcinoma (CESCC) patients with cervical lymph node metastasis (CLNM). Methods: We performed a retrospective analysis on 180 CESCC patients (141 males, 39 females; with median age of 59 years, ranging in age from 24 to 76) who underwent surgical treatment at the Cancer Hospital, Chinese Academy of Medical Sciences from February 2001 to October 2023. Based on the regions of cervical lymph node metastasis, patients were divided into three groups: non-lymph node metastasis group, central compartment metastasis-only group, and a combined central and lateral cervical metastasis group. We aimed to compare the impact of cervical lymph node metastasis regions and different preoperative intervention regimens on survival outcomes. The 3-year and 5-year overall survival (OS) rates were estimated using the Kaplan-Meier method, and univariate and multivariate Cox regression analyses were performed to identify factors associated with prognosis. Results: Cervical lymph node dissection was performed in 123 patients with CLNM. Among all patients, 54 patients received preoperative chemotherapy, and 19 patients received preoperative chemotherapy combined with immunotherapy. The median OS in the entire cohort was 46 months, with 3-and 5-year OS rates of 58.04% and 42.02%, respectively. Patients without CLNM exhibited significant higher 5-year OS rate than those with CLNM (54.86% vs. 35.69%, χ2=7.29, P=0.007). No significant difference in 5-year OS rate was observed between the central neck lymph node metastasis-only group (54 patients) and the combined central and lateral neck lymph node metastasis group (69 patients) (35.98% vs. 35.36%, χ2=0.17, P=0.676). Preoperative chemotherapy and chemoimmunotherapy significantly reduced the mortality risk (HR=0.61 and 0.12, respectively; both P<0.05). Regarding the 3-year OS rate, there was a significant difference among the chemoimmunotherapy group (90.91%), chemotherapy-only (65.89%) and no-preoperative chemotherapy (49.68%) groups (overall χ2=11.22, P=0.004). Compared with patients who did not receive radiotherapy, preoperative and postoperative radiotherapy were not associated with a significant reduction in mortality risk (both P>0.05). Conclusions: After cervical lymph node dissection, the surgical efficacy of lateral CLNM patients resembles that of patients with central CLNM. Preoperative chemoimmunotherapy significantly improves the OS rates of CESCC patients. 目的: 探讨颈段食管鳞状细胞癌(鳞癌)伴随颈部淋巴结转移患者的手术疗效。 方法: 回顾性分析2001年2月至2023年10月中国医学科学院肿瘤医院接受手术治疗的180例颈段食管鳞癌患者的临床资料,男性141例,女性39例,年龄24~76岁(中位年龄59岁)。根据颈部淋巴结转移区域,将患者分为无淋巴结转移组、仅中央区转移组以及中央区和侧颈区联合转移组,比较淋巴结转移范围及不同术前干预方案对于生存结局的影响。采用Kaplan-Meier法估计3年及5年总体生存(OS)率,通过单因素及多因素Cox回归分析讨论与预后相关的因素。 结果: 本组123例患者因颈部淋巴结转移行颈部淋巴清扫术,54例接受术前化疗,19例接受术前化疗联合免疫治疗。全组中位OS为46个月,3年OS率为58.04%,5年OS率为42.02%。无颈部淋巴结转移组(57例)患者的5年OS率为54.86%,存在颈部淋巴结转移的5年OS率为35.69%,差异有统计学意义(χ2=7.29,P=0.007)。在颈部淋巴结转移患者中,中央区淋巴结转移组(54例)相比于中央区和侧颈区淋巴结转移组(69例)患者的5年OS率差异无统计学意义(35.98%比35.36%,χ2=0.17,P=0.676)。术前化疗或化疗联合免疫治疗可以降低患者死亡风险(HR为0.61和0.12,P值均<0.05)。3年OS率方面,接受术前化疗联合免疫治疗组(90.91%)、术前化疗组(65.89%)和术前未行化疗组(49.68%)差异有统计学意义(χ2=11.22,P=0.004)。术前放疗和术后放疗的患者死亡风险相比于未放疗患者差异无统计学意义(P值均>0.05)。 结论: 对于侧颈区淋巴结转移的颈段食管鳞癌患者,接受颈清扫后,其手术疗效与仅存在中央区淋巴结转移的患者相近。术前行化疗联合免疫治疗可有效提高患者OS率。.
引用
- Zhang F, Wang Z, Zhang XW, et al. [A retrospective study on the therapeutic effect of neck dissection in patients with cervical esophageal squamous cell carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2026. PMID: 42037026. doi:10.3760/cma.j.cn115330-20260213-00094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。